GH1 and neoplasm: Alonso et al. demonstrated in their study involving 21 patients who underwent repeat GKRS for growth hormone (GH)-secreting PAs, that 15 patients (83%) had tumor control after a median follow-up of 3.4 years; however, the indication for repeat GKRS was hormonal activity rather than tumor growth [2].